Takeda helps Altos develop gastroparesis compound; exercises option to buy firm
Executive Summary
Takeda Pharmaceutical Co. Ltd. further enhanced its focus on the gastrointestinal disease market and penned a deal with small biotech Altos Therapeutics LLC to develop Altos' ATC1906, an early-stage compound in studies for gastroparesis. Takeda also has an option to buy the firm at a later date.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice